Abstract:Inhibitors of histone deacetylases (HDACIs) have emerged as a new class of drugs for the treatment of human cancers and other diseases because of their effects on cell growth, differentiation, and apoptosis. In this study we have developed several quantitative structure-activity relationship (QSAR) models for 59 chemically diverse histone deacetylase class 1 (HDAC1) inhibitors. The variable selection k nearest neighbor (kNN) and support vector machines (SVM) QSAR modeling approaches using both MolconnZ and MOE chemical descriptors generated from two-dimensional rendering of compounds as chemical graphs have been employed. We have relied on a rigorous model development workflow including the division of the data set into training, test, and external sets and extensive internal and external validation. Highly predictive QSAR models were generated with leave-one-out cross-validated (LOO-CV) q2 and external R2 values as high as 0.80 and 0.87, respectively, using the kNN/MolconnZ approach and 0.93 and 0.87, respectively, using the SVM/MolconnZ approach. All validated QSAR models were employed concurrently for virtual screening (VS) of an in-house compound collection including 9.5 million molecules compiled from the ZINC7.0 database, the World Drug Index (WDI) database, the ASINEX Synergy libraries, and other commercial databases. VS resulted in 45 structurally unique consensus hits that were considered novel putative HDAC1 inhibitors. These computational hits had several novel structural features that were not present in the original data set. Four computational hits with novel scaffolds were tested experimentally, and three of them were confirmed active against HDAC1, with IC50 values for the most active compound of 1.00 microM. The fourth compound was later identified to be a selective inhibitor of HDAC6, a Class II HDAC. Moreover, two of the confirmed hits are marketed drugs, which could potentially facilitate their further development as anticancer agents. This study illustrates the power of the combined QSAR-VS method as a general approach for the effective identification of structurally novel bioactive compounds.

QSAR Studies of Antitumor Inhibitors of Histone Deacetylases

QSAR studies of antitumor inhibits of histone deacetylases

Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors.

3D Qsar and Docking Studies of A Series of Histone Deacetylase Inhibitors

QSAR Studies of Histone Deacetylase (HDAC) Inhibitors by CoMFA, CoMSIA, and Molecular Docking.

Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation.

3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.

QSAR Studies of Antitumor Inhibitors Lavendustin A Analogues

3D-Qsar Study on Apicidin Inhibit Histone Deacetylase

2D-QSAR Studies on Antitumor Quinolones with the Modification on Site C-3

Screening of Selective Histone Deacetylase Inhibitors by Proteochemometric Modeling

Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study

3d-Qsar And Molecular Docking Studies On Benzotriazoles As Antiproliferative Agents And Histone Deacetylase Inhibitors

Design, Synthesis and Biological Evaluation of Novel Histone Deacetylase Inhibitors Based on Virtual Screening

Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Discovery of A Series of Hydroximic Acid Derivatives As Potent Histone Deacetylase Inhibitors

Predicting the Activity of Hydroxamic Acid Analogues

Syntheses and Biological Evaluation of Novel Hydroxamic Acid Derivatives Containing Purine Moiety As Histone Deacetylase Inhibitors

Design, Synthesis and Preliminary Bioactivity Evaluations of Substituted Quinoline Hydroxamic Acid Derivatives As Novel Histone Deacetylase (hdac) Inhibitors

Identification of Ligand Features Essential for HDACs Inhibitors by Pharmacophore Modeling.

Synthesis and Biological Evaluation of a New Series of Histone Deacetylases Inhibitors